Search Clinical Trials in the EU

Duration

16-20 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

1-20 of 112 trials

Alpelisib for Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (MCAP)

We are studying whether alpelisib can improve adaptive behavior and overall health in children and adults with MCAP. The trial will also assess the safety and effects of the treatment on brain and spinal cord health.

PIK3CA Related Overgrowth SpectrumMegalencephaly-Capillary Malformation-Polymicrogyria Syndrome>2 yearsEfficacy phase (II)16-20 visits Post-Trial Drug Access Investigational MedicinesInternal MedicineNeurologyPediatrics

Early Breast Cancer: Imlunestrant vs Standard Therapy

We are studying a new treatment called imlunestrant for patients with early breast cancer who have already received 2 to 5 years of standard therapy. The goal is to see if it helps reduce the risk of cancer returning compared to current treatments.

Breast Cancer>2 yearsConfirmation phase (III)16-20 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Serious Bacterial Infections in Children: Aztreonam-Avibactam Study

We are investigating a new treatment for serious gram-negative bacterial infections in children aged 9 months to under 18 years. The study compares this treatment to the best available therapy to assess safety and effectiveness.

Hospital-Acquired PneumoniaVentilator-Associated PneumoniaComplicated Gram-Negative Bacterial Infections≤3 monthsEfficacy phase (II)16-20 visits No Placebo Investigational Medicines Partially RemoteInfectious DiseasesPediatrics

Polymyalgia Rheumatica: Secukinumab Injection Study

We are studying whether secukinumab, combined with a glucocorticoid taper, can help patients with polymyalgia rheumatica achieve better remission compared to a placebo. This trial also looks at the safety and quality of life for participants.

Polymyalgia Rheumatica1-2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Calcific Aortic Valve Stenosis: Pelacarsen (TQJ230) Study

We are studying whether the medication pelacarsen can slow the progression of calcific aortic valve stenosis in patients with high lipoprotein(a) levels. This trial will help us understand its effects compared to a placebo.

Calcific Aortic Valve Stenosis>2 yearsEfficacy phase (II)16-20 visits Investigational Medicines Cost ReimbursementCardiologyInternal Medicine

Prostate Cancer: 177Lu-PSMA-617 Treatment Study

We are evaluating whether adding 177Lu-PSMA-617 to standard treatment helps men with metastatic hormone-sensitive prostate cancer who are not responding well to current therapies. The goal is to see if this combination improves survival and disease control.

Hormone-sensitive Metastatic Prostate Cancer3-6 monthsConfirmation phase (III)16-20 visits No Placebo Standard Medicines Partially RemoteOncologyUrology

Multiple Sclerosis: BIIB091 Treatment Study

We are studying the safety of BIIB091 alone and with Diroximel Fumarate in adults with relapsing forms of multiple sclerosis. The goal is to see how these treatments affect brain inflammation.

Relapsing Multiple Sclerosis1-2 yearsEfficacy phase (II)16-20 visits Investigational Medicines Cost ReimbursementNeurology

Ovarian Cancer: NiraParib Maintenance Study

We are studying whether three cycles of chemotherapy followed by the drug niraparib is as effective as six cycles for patients with advanced ovarian cancer. This trial focuses on those who have had their tumors completely removed and are HRD-positive.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)16-20 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteOncology

Alopecia Areata: Baricitinib for Children

We are studying whether Baricitinib helps children aged 6 to under 18 with Alopecia Areata by comparing it to a placebo. This trial aims to find out if the medication can improve hair regrowth.

Alopecia Areata6-12 monthsConfirmation phase (III)16-20 visits Standard MedicinesDermatologyPediatrics

Fronto-Temporal Dementia: LY3884963 Treatment Study

We are testing a new injection for patients with fronto-temporal dementia due to progranulin mutations. The study aims to evaluate its safety and effects on a key protein related to the disease.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Osteogenesis Imperfecta: Romosozumab vs. Bisphosphonates

We are studying whether romosozumab can reduce fractures and improve bone density in children and adolescents with osteogenesis imperfecta compared to bisphosphonates. This trial will help us understand the safety and effectiveness of this new treatment.

Brittle Bone Disease1-2 yearsConfirmation phase (III)16-20 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteOrthopedics and TraumatologyPediatrics

Tislelizumab for Cancer Patients with Residual Disease

We are studying whether tislelizumab can help cancer patients who still have detectable disease after standard treatment. The goal is to see if it improves their chances of staying cancer-free compared to a placebo.

Pancreatic CancerSoft Tissue SarcomaNon-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visits Standard Medicines Partially RemoteGastroenterologyOncologyPulmonology

Advanced Non-Small Cell Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have a specific genetic mutation. This trial compares the effects of the combination treatment to chemotherapy alone.

Non-Small Cell Lung Cancer6-12 monthsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncologyPulmonology

Hidradenitis Suppurativa: Upadacitinib Study

We are testing Upadacitinib in adults and adolescents with moderate to severe Hidradenitis Suppurativa who haven't responded to other treatments. The goal is to see if it is more effective and safe than a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteDermatology

CMV Prevention in Lung Transplant Recipients: Letermovir Study

We are studying whether letermovir can better prevent CMV infection in lung transplant recipients compared to standard treatment with valganciclovir. This research may help improve care for patients at risk of CMV disease.

Lung Transplant Patients (D+/R-)1-2 yearsEfficacy phase (II)16-20 visits No Placebo Investigational Medicines Partially RemoteInfectious DiseasesPulmonology

Chronic Pouchitis in Children: Vedolizumab IV Study

We are testing the intravenous medication vedolizumab in children with active chronic pouchitis to see if it helps them achieve remission. The study will also look at how well the treatment is tolerated and its overall effectiveness.

Pouchitis1-2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyPediatrics

Advanced Breast Cancer: Capivasertib with CDK4/6 Inhibitors

We are studying a new treatment combining capivasertib with CDK4/6 inhibitors and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this combination improves treatment outcomes compared to standard therapies.

Hormone Receptor-Positive and HER2-Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab with Chemotherapy

We are studying if adding Fianlimab to Cemiplimab and chemotherapy is safer and more effective for adults with early-stage non-small cell lung cancer that can be surgically removed. This trial will help us understand the best treatment options for these patients.

Resectable Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visits Standard Medicines Cost Reimbursement Partially RemoteOncology

Multiple Myeloma: Innovative Treatment Approaches

We are studying new methods to monitor multiple myeloma in patients who have not yet been treated. This trial compares different treatment combinations, including a stem cell transplant, to see which is more effective.

Multiple Myeloma6-12 monthsEfficacy phase (II)16-20 visits No Placebo Investigational MedicinesHematologyOncology

Metastatic Non-Small Cell Lung Cancer: ONC-392 vs. Docetaxel

We are studying a new treatment, ONC-392, to see if it helps patients with metastatic non-small cell lung cancer who have progressed on immunotherapy. The goal is to compare its effectiveness and safety against the standard treatment, docetaxel.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Search Clinical Trials in the European Union